嵌合抗原受体T细胞治疗多发性骨髓瘤研究进展

Progress of chimeric antigen receptor T-cell in treatment of multiple myeloma

靶向B细胞成熟抗原(BCMA)的嵌合抗原受体T细胞(CAR-T)免疫疗法已经在复发难治多发性骨髓瘤中显示出显著疗效。随着CAR-T疗法的快速发展,靶向BCMA的CAR-T疗法不断优化,新靶点、双靶点和通用型CAR-T等新产品相继出现,第64届美国血液学会年会上更新了多项相关临床研究数据。

Chimeric antigen receptor T-cell(CAR-T)immunotherapy targeting B-cell maturation antigen(BCMA)has shown significant efficacy in relapsed/refractory multiple myeloma.With the rapid development of CAR-T therapies,CAR-T therapies targeting BCMA continue to be optimized,and new products such as new targets,dual-targets and universal CAR-T are arriving successively.Data from several relevant clinical studies were updated at the 64th American Society of Hematology Annual Meeting.